AU2019390863B2 - Heterocyclic compound - Google Patents

Heterocyclic compound Download PDF

Info

Publication number
AU2019390863B2
AU2019390863B2 AU2019390863A AU2019390863A AU2019390863B2 AU 2019390863 B2 AU2019390863 B2 AU 2019390863B2 AU 2019390863 A AU2019390863 A AU 2019390863A AU 2019390863 A AU2019390863 A AU 2019390863A AU 2019390863 B2 AU2019390863 B2 AU 2019390863B2
Authority
AU
Australia
Prior art keywords
group
urea
chloro
substituted
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019390863A
Other languages
English (en)
Other versions
AU2019390863A1 (en
AU2019390863A2 (en
Inventor
Yasuyoshi Arikawa
Hiroshi Banno
Takaharu Hirayama
Shinichi Imamura
Yoshiteru Ito
Youichi Kawakita
Noriyuki NII
Toshio Tanaka
Hidekazu Tokuhara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2019390863A1 publication Critical patent/AU2019390863A1/en
Publication of AU2019390863A2 publication Critical patent/AU2019390863A2/en
Application granted granted Critical
Publication of AU2019390863B2 publication Critical patent/AU2019390863B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2019390863A 2018-11-28 2019-11-27 Heterocyclic compound Active AU2019390863B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-222530 2018-11-28
JP2018222530 2018-11-28
PCT/JP2019/046261 WO2020111087A1 (ja) 2018-11-28 2019-11-27 複素環化合物

Publications (3)

Publication Number Publication Date
AU2019390863A1 AU2019390863A1 (en) 2021-06-24
AU2019390863A2 AU2019390863A2 (en) 2021-07-01
AU2019390863B2 true AU2019390863B2 (en) 2025-02-20

Family

ID=70853784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019390863A Active AU2019390863B2 (en) 2018-11-28 2019-11-27 Heterocyclic compound

Country Status (16)

Country Link
US (4) US12152027B2 (cg-RX-API-DMAC10.html)
EP (1) EP3888652A4 (cg-RX-API-DMAC10.html)
JP (2) JP6972384B2 (cg-RX-API-DMAC10.html)
KR (2) KR102646470B1 (cg-RX-API-DMAC10.html)
CN (2) CN113038948B (cg-RX-API-DMAC10.html)
AU (1) AU2019390863B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021009994A2 (cg-RX-API-DMAC10.html)
CA (1) CA3120774A1 (cg-RX-API-DMAC10.html)
IL (2) IL283368B2 (cg-RX-API-DMAC10.html)
MX (2) MX2021005877A (cg-RX-API-DMAC10.html)
MY (1) MY209902A (cg-RX-API-DMAC10.html)
PH (1) PH12021551251A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202105652XA (cg-RX-API-DMAC10.html)
TW (2) TWI848400B (cg-RX-API-DMAC10.html)
WO (1) WO2020111087A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202104402B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
EP4163280A4 (en) * 2020-05-27 2024-06-05 Takeda Pharmaceutical Company Limited METHOD FOR PRODUCING A HETEROCYCLIC COMPOUND
WO2022081967A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2022174253A1 (en) * 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
US20250188081A1 (en) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2288521A1 (fr) 1974-10-25 1976-05-21 Merck Patent Gmbh Nouvelles penicillines et procede pour leur preparation
CA2222687A1 (en) * 1995-05-31 1996-12-05 Masami Muraoka Novel naphthyridine derivatives
GB9720052D0 (en) * 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
JP6545197B2 (ja) * 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
EP3374361A1 (en) * 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
WO2018020474A1 (en) * 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
US10689366B2 (en) * 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation
US20200111087A1 (en) * 2018-10-08 2020-04-09 Jinlei Zhou Method for encrypting digital contract document between contractors
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Also Published As

Publication number Publication date
IL283368A (en) 2021-07-29
KR20210092301A (ko) 2021-07-23
SG11202105652XA (en) 2021-06-29
NZ777412A (en) 2024-05-31
TWI848400B (zh) 2024-07-11
CN118420620A (zh) 2024-08-02
US20250034141A1 (en) 2025-01-30
CN113038948B (zh) 2024-07-12
TWI784213B (zh) 2022-11-21
TW202438498A (zh) 2024-10-01
JP6972384B2 (ja) 2021-11-24
MX2024003064A (es) 2024-03-27
US11897879B2 (en) 2024-02-13
MX2021005877A (es) 2021-07-16
JP2022017461A (ja) 2022-01-25
US11230545B2 (en) 2022-01-25
WO2020111087A9 (ja) 2021-01-21
TW202306956A (zh) 2023-02-16
MY209902A (en) 2025-08-09
BR112021009994A2 (pt) 2021-08-17
US20210332045A1 (en) 2021-10-28
PH12021551251A1 (en) 2021-12-06
AU2019390863A1 (en) 2021-06-24
US20220089595A1 (en) 2022-03-24
TW202039484A (zh) 2020-11-01
JP7434249B2 (ja) 2024-02-20
IL303962B2 (en) 2026-05-01
ZA202104402B (en) 2023-01-25
IL303962B1 (en) 2026-01-01
IL303962A (en) 2023-08-01
EP3888652A4 (en) 2022-10-19
EP3888652A1 (en) 2021-10-06
JPWO2020111087A1 (ja) 2021-09-27
KR102646470B1 (ko) 2024-03-11
CN113038948A (zh) 2021-06-25
CA3120774A1 (en) 2020-06-04
IL283368B2 (en) 2025-01-01
US12152027B2 (en) 2024-11-26
KR20220019848A (ko) 2022-02-17
US20220048916A1 (en) 2022-02-17
KR102359143B1 (ko) 2022-02-08
AU2019390863A2 (en) 2021-07-01
WO2020111087A1 (ja) 2020-06-04
IL283368B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US11897879B2 (en) Heterocyclic compound
KR102558066B1 (ko) Tam 억제제로서 피롤로트리아진 화합물
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
CA3021185C (en) Fused heterocyclic compound
CN113164481B (zh) 环烷-1,3-二胺衍生物
JP2021525810A (ja) トリプトファン異化のモジュレーター
EP3514149B1 (en) Heterocyclic amide compound
CN116249696B (zh) 嘧啶酮类化合物及其用途
RU2808435C2 (ru) Гетероциклическое соединение
HK40051951A (zh) 杂环化合物
HK40051951B (en) Heterocyclic compound
HK40109453A (en) Heterocyclic compounds
HK40091563B (en) Pyrimidinone compounds and uses thereof
HK40091563A (en) Pyrimidinone compounds and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 JUN 2021

FGA Letters patent sealed or granted (standard patent)